Category Archives: Patent

Time to put a stop to the abuse of orphan drug regulation- the latest scandal

10th Jan 2019, New Delhi Source: Medicines Law and Policy Today, the Dutch Medical Journal (Nederlands Tijdschrift voor Geneeskunde) reported on the case of lutetium-octreotaat, a cancer drug developed by researchers in the Dutch Erasmus medical centre in Rotterdam. For … Continue reading

Posted in Access to Medecines, Cancer, Innovation, orphan drug, Patent, Price hikes, Pricing | Leave a comment

People living with hepatitis C and HIV challenge evergreening patents on lifesaving hepatitis C drugs in India

New Delhi, 10 July 2018: Delhi Network of Positive People (DNP+) has filed today two patent oppositions before the Indian patent office, challenging additional patent claims by US pharmaceutical corporation-Gilead Sciences for the hepatitis C medicines sofosbuvir and velpatasvir. These … Continue reading

Posted in Drug prices, Hepatitis C, Indian Patent Law, Patent, Patent Opposition, Sec 3 (d) | Tagged , | Leave a comment

The switch from patents to state-dependent prizes for technological innovation

by Hwan C. Lin, Journal of Macroeconomics Volume 50, December 2016, Pages 193-223 Highlights •Examine the intertemporal bounty (IB) system as an alternative to patents. •The IB system rewards innovation with a bounty claim to state-dependent prizes (called “intertemporal bounties”) over time. … Continue reading

Posted in Innovation, Patent, Patent examination system, Uncategorized | Leave a comment

The problem with high drug prices isn’t ‘foreign freeloading,’ it’s the patent system

by Tahir Amin, CNBC | June 27, 2018 One in four Americans are unable to fill prescriptions due to high prices. Today’s drug patent monopolies are stronger than at any point in the last century, raising prescription prices. Until the … Continue reading

Posted in Evergreening, Patent, Patent examination system, Patent Opposition, Uncategorized | Leave a comment

Document exclusivity weakens Norwegian pandemic preparedness

Source: Dagens Medisin | June 20, 2018 IMAGINE THAT A large global o, break of contagious disease also includes Norway, such as a new flu-like disease with high risk of transmission and mortality. Imagine that there is only one effective drug, … Continue reading

Posted in Compulsory Licensing, Patent, Patents | Leave a comment

MSF challenges Gilead’s unmerited patent in China for lifesaving hepatitis C medicine, Affordable generic versions from China could save millions of people’s lives

Source: Medecins Sans Frontieres |June 19, 2018 The international medical humanitarian organisation Médecins Sans Frontières (MSF) today filed a legal patent challenge at China’s State Intellectual Property Office (SIPO), requesting the invalidation of the patent granted to US pharmaceutical corporation … Continue reading

Posted in Hepatitis C, Patent, Patent Enforcement | Leave a comment

WIPO: Proposal to amend PCT Regulations undermines TRIPS flexibilities

Geneva, 15 June (TWN) – A proposal to amend a treaty regulation at the World Intellectual Property Organization (WIPO) will compromise TRIPS flexibilities, especially in relation to the scope of patentability for national patent offices. The International Bureau (i.e. WIPO … Continue reading

Posted in Patent, TRIPS, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized, WIPO | Leave a comment